NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.


This presentation begins with a brief overview of relevant disease state information about severe asthma and eosinophils. It will cover the evolving concept of phenotyping and its role in clinical practice. A discussion about eosinophils as a biomarker in severe asthma will follow. The presentation concludes with a review of the clinical development program for NUCALA.

825656R0 September 2017